Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumorsS. Champiat, et al. ESMO 2024 Abstract disponible sur le site de l’ESMO – Télécharger abstract and the poster